热门资讯> 正文
贝顿、迪金森被指控阻碍疝气网片市场竞争
2025-12-23 06:54
- Tela Bio (TELA) has filed a lawsuit accusing Becton, Dickinson (BDX) of stymying competition in the US market for surgical hernia mesh.
- The lawsuit, filed on Dec. 19 in a Philadelphia federal court, claims that Becton, Dickinson used its dominance in permanent hernia mesh and resorbable hernia mesh to crowd out Tela Bio's competing OviTex product.
- Tela Bio is accusing Becton, Dickinson of retribution against hospitals and other healthcare providers for purchasing OviTex as well as using long-term contracts to entice customers to purchases hernia mesh only from Becton Dickinson, Reuters reported.
- In October 2024, Becton, Dickinson said it settled the "vast majority" of claims alleging safety concerns with its hernia mesh products.
More on Becton, Dickinson, TELA Bio
- Becton, Dickinson: Our New, Long, Special Situation Investment
- TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
- Becton, Dickinson and Company 2025 Q4 - Results - Earnings Call Presentation
- Waters raised to Outperform at Wolfe on BD Life Sciences deal
- 1578 Partners initiates new position in Becton, Dickinson and Company in Q3
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
